
Protagonist and Takeda Announce Positive Topline Results from Phase 3 Study of Rusfertide in Patients with Rare Blood ...
Protagonist Therapeutics, Inc. and Takeda announced positive topline results for the Phase 3 VERIFY study, in which phlebotomy-dependent patients with polycythemia vera (PV) were randomized to treatment with either rusfertide or placebo, as an add-on to …